ADVBHIGH SIGNALFINANCIAL10-Q

ADVB completed a major divestiture, selling its Hong Kong subsidiary and all associated intellectual property for $23,000 in December 2025, generating a substantial gain that drove reported profitability.

This asset sale represents a significant strategic shift for the company, as it disposed of its entire Hong Kong operations including valuable intellectual property assets. While the transaction generated a meaningful one-time gain that resulted in net income of $6.5M for the six-month period, the underlying operating performance shows continued cash outflows of $1.1M, indicating ongoing operational challenges. The disposal suggests either capital needs or strategic repositioning away from these assets.

Comparing 2026-02-13 vs 2025-11-19View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position improved substantially following the asset divestiture, with current assets growing to $10.7M and total liabilities declining meaningfully to $1.4M, strengthening the balance sheet considerably. Operating expenses remained relatively stable with R&D spending declining modestly to $186K, while capital expenditures dropped significantly to just $2K. Despite the positive net income driven by the disposal gain, negative operating cash flows of $1.1M highlight that core business operations remain cash-consumptive.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-91.1%
$20K$2K

Capex reduced 91.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+83.6%
$5.8M$10.7M

Current assets grew 83.6% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+73.8%
$6.2M$10.9M

Asset base grew 73.8% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-58.8%
$3.0M$1.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-57.7%
$3.2M$1.4M

Liabilities reduced 57.7% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-21%
$236K$186K

R&D spending cut 21% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-11-19
ADDED
On December 23, 2025, the Company entered into an agreement (the Agreement ) with an unrelated third party, Wei Ha Hui (the Buyer ), pursuant to which the Company agreed to sell 100 % of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the Hong Kong Subsidiary ), for an aggregate purchase price of US$ 23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.
All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 31, 2025.
7 However, for the six-month period ended December 31, 2025, although the Company reported net income of $ 6,471,020 , this was primarily attributable to a gain of $ 7,346,684 generated from the disposal of Advanced Biomed (HK) Limited and its subsidiary during the period.
In addition, the Company had net cash outflows of $ 1,123,900 from operating activities for the six-month periods ended December 31, 2025.
(h) Related parties We adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions for the six-month periods ended December 31, 2025 and 2024.
+7 more — sign up free →
REMOVED
7 However, for the three-month periods ended September 30, 2025, the Company reported net loss of $ 386,901 .
In addition, the Company had net cash outflows of $ 610,342 from operating activities for the three-month periods ended September 30, 2025.
(h) Related parties We adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions for the three-month periods ended September 30, 2025 and 2024.
As of September 30, 2025 and June 30, 2025, the Company had no remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd.
The Company has already started the registration process and plans to start the clinical research in January 2026, which are expected to end in June 2026, and we expect to obtain the required registration certificate by October 2027.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →